Home Dialysis to Benefit These Undervalued Providers
DaVita and Fresenius are best positioned to capture the incremental profits from home therapy.
We expect DaVita (DVA) and Fresenius Medical Care (FMS)/(FME) to benefit as higher-margin home dialysis treatments gain share, with growth of nearly 8% set to outpace in-center dialysis growth of roughly 2.6%, driven by increasing interest across the industry to lower treatment costs. Specifically, the U.S. Department of Health and Human Services has proposed potential changes to reimbursement policy that are likely to encourage home treatment for kidney failure. Home therapy has been making a slow but consistent resurgence over the past decade; in this piece, we examine the competitive implications for DaVita and Fresenius should a more meaningful mix shift be on the horizon. Ultimately, we think these companies’ established clinic networks, along with the sticky relationship among provider, physician, and patient, will prove too high a barrier for competitors. While the stocks of both companies look cheap following recent underperformance, we think DaVita’s nearly 30% discount to our fair value estimate presents a compelling investment opportunity.
Adoption of Home-Based Dialysis Therapy Has Been Slow
The two primary modalities amenable to at-home treatment are hemodialysis and peritoneal dialysis. Home hemodialysis is similar to treatments done in the clinic--patients use a machine to remove blood from the body, pass it through an external filter, and return the cleaned blood to the body. These treatments are typically shorter but more frequent than in-center hemodialysis. Peritoneal dialysis requires a tube to be inserted into a patient’s abdomen to use his or her own abdominal membrane (peritoneum) as the filter. The patient either inserts and removes dialysis solution manually throughout the day or uses a cycler machine to automate these exchanges at night.
Jake Strole does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.